Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

A reminder to all members that you agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


130 Pages (Click to Jump) V   1 2 3 4 > »    
 
  
Reply to this topic

UNS, UNILIFE CORPORATION
nipper
post Posted: May 9 2016, 01:53 PM
  Quote Post


Posts: 7,505
Thanks: 2548


In Reply To: henrietta's post @ Feb 24 2016, 08:03 PM

QUOTE
Countering the flow of upbeat biotech tidings, shares in serial loss maker Unilife (UNS) plunged 26 per cent after the US-based company revealed "violations of company policies and procedures and possible violations of law and regulation by the company's former CEO and chairman … who resigned in 2015.''

The prefilled syringe maker did not name the individual. But it presumably refers to founder, long-time CEO and chairman, Alan Shortall, who actually resigned in March 15 this year, "effective immediately". The probe "has not to date discovered any financial loss to the company.''
The Australian



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
henrietta
post Posted: Feb 24 2016, 08:03 PM
  Quote Post


Posts: 4,329
Thanks: 719


In Reply To: plastic's post @ Feb 24 2016, 09:00 AM

" If that isn't going to give it lift, what will? "

Substantial and increasing sales. Plus another contract or two. Plus a management shake-up.
That should do it.

Cheers
J



--------------------
"Sometimes I sits and thinks, and sometimes I just sits." Satchel Paige

"No road is long with good company." Traditional

Said 'Thanks' for this post: floyd  pacestick  
 
pacestick
post Posted: Feb 24 2016, 10:49 AM
  Quote Post


Posts: 339
Thanks: 70


In Reply To: plastic's post @ Feb 24 2016, 09:00 AM

I have no idea . They have dealt with the immediate short term financial crisis . There will be more contracts to come both from AMGEN and others over the next twelve months as the company edges towards profitability

 
plastic
post Posted: Feb 24 2016, 09:00 AM
  Quote Post


Posts: 10,256
Thanks: 302


If that isn't going to give it lift, what will?



--------------------
What did Uncle Mel do to us?
 
pacestick
post Posted: Feb 23 2016, 03:47 AM
  Quote Post


Posts: 339
Thanks: 70


In Reply To: plastic's post @ Feb 22 2016, 03:15 PM

Unilife and Amgen Enter Strategic Collaboration for Injectable Drug Delivery Systems

Amgen to invest up to $75 million in leading technology platform
Collaboration includes license agreement and master development and supply agreement





YORK, Pa., Feb. 22, 2016 /PRNewswire/ -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS) today announced a strategic collaboration with Amgen (NASDAQ: AMGN), a leading biotechnology company, for injectable drug delivery systems. The collaboration, which includes licensing, investment, development and supply agreement components, is centered upon the use of Unilife's portfolio of prefilled, customizable wearable injectors for medicines to enhance the patient experience.

Under the terms of the collaboration, Unilife has granted Amgen exclusive rights to Unilife's wearable injectors within select drug classes for use with certain Amgen assets, while preserving rights previously granted to other Unilife customers. Unilife has also granted Amgen non-exclusive rights to all proprietary Unilife delivery systems within the therapeutic areas of oncology, inflammation, bone health, nephrology, cardiovascular and neuroscience.

"Unilife looks forward to a long-term strategic collaboration with Amgen to drive value for patients, prescribers and payers," said Ian Hanson, senior vice president and general manager of Unilife's Wearable Injector business unit. "Unilife is pleased to advance its leadership position in the wearable injectors market to meet growing demand for biologics and other medicines. Our prefilled, pre-assembled and ready-to-inject delivery systems are easy-to-use and enhance patient experience."

"We are pleased to enter this collaboration with Unilife," said Alison Moore, senior vice president of Process Development at Amgen. "One important pillar of Amgen's strategy is to invest in leading drug delivery technologies to more effectively meet the needs of patients suffering from serious illnesses. Unilife continues to develop technology that could provide patients with innovative and meaningful enhancements to drug administration."

Under the strategic collaboration, Unilife can receive up to $75 million. At closing, Amgen paid a nonrefundable $20 million license fee and purchased a $30 million senior secured convertible note from Unilife. Amgen may purchase up to an additional $25 million in senior secured convertible notes over the next two years ($15 million in January 2017 and $10 million in January 2018). These payments are in addition to Amgen's $15 million payment to Unilife in connection with the exclusivity letter entered into on December 31, 2015.

In addition to these payments, Unilife expects to generate future revenue from the strategic collaboration with Amgen. The collaboration includes a master development and supply agreement that captures key terms for the development, production and supply of Unilife delivery systems. Development programs will commence in 2016.

About Unilife

Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S.-based developer and commercial supplier of injectable drug delivery systems. Unilife's portfolio of innovative, differentiated products includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, insulin delivery systems, ocular delivery systems and novel systems. Products within each platform are customizable to address specific customer, drug and patient requirements. Unilife's global headquarters and manufacturing facilities are located in York, Penn. For more information, visit www.unilife.com

General: UNIS-G

Investor Contacts (U.S.):

Investor Contacts (Australia)

Todd Fromer / Garth Russell

Jeff Carter

KCSA Strategic Communications

Unilife Corporation

P: + 1 212-682-6300

P: + 61 2 8346 6500



Forward-Looking Statements
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K, those described in the "Risk Factors" set forth in Unilife's prospectus supplement, dated as of and filed with the U.S. Securities and Exchange Commission on February 22, 2016, and those described from time to time in other reports which we file with the U.S. Securities and Exchange Commission.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/un...-300223649.html

SOURCE Unilife Corporation



 
plastic
post Posted: Feb 22 2016, 03:15 PM
  Quote Post


Posts: 10,256
Thanks: 302


Makes me wonder if they are going to be left at the alter.



--------------------
What did Uncle Mel do to us?
 

Featured Stock Stories





plastic
post Posted: Feb 22 2016, 02:33 PM
  Quote Post


Posts: 10,256
Thanks: 302


Why is it only UNS Amgen wish to be seen to be associated with? AMGN specializes in things of the blood. Is there nothing else on the ASX they would want to be in on? I easily imagine there is, therefore I am a little querulous as to why they limit their known associations on the ASX to just UNS.



--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Feb 8 2016, 09:45 AM
  Quote Post


Posts: 10,256
Thanks: 302


If there is no notice to the exchange of EGM cancellation, then does that mean it isn't cancelled? Other business to attend to perhaps. Hence the need for the extension?



--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Feb 8 2016, 09:22 AM
  Quote Post


Posts: 10,256
Thanks: 302


UNS is not the lead act of the biotech show it would seem. Wonder which is.



--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Feb 8 2016, 04:09 AM
  Quote Post


Posts: 10,256
Thanks: 302


In Reply To: henrietta's post @ Feb 7 2016, 07:48 PM

Stranger things have happened. They could've been gazumped or ditched the bride at the alter for whatever reason. $15m is nothing to them.

It's like if AMGN are interested then so will GILD be and a suite of others.

And you have to admit, over the time there has been little that is straight up about this company.





--------------------
What did Uncle Mel do to us?
 
 


130 Pages (Click to Jump) V   1 2 3 4 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING